CSL Limited (CSLLY)
USD 81.65
(0.89%)
USD 81.65
(0.89%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | 10.52 Billion USD | -34.39% |
| 2023 | 10.67 Billion USD | 1471.56% |
| 2022 | -778.6 Million USD | -119.47% |
| 2021 | 3.99 Billion AUD | -16.68% |
| 2020 | 4.79 Billion AUD | 19.81% |
| 2019 | 4 Billion AUD | 12.13% |
| 2018 | 3.57 Billion AUD | 14.08% |
| 2017 | 3.13 Billion AUD | 21.03% |
| 2016 | 2.58 Billion AUD | 50.03% |
| 2015 | 1.72 Billion AUD | 34.53% |
| 2014 | 1.28 Billion AUD | 39.81% |
| 2013 | 916.7 Million AUD | 668.88% |
| 2012 | 119.22 Million AUD | 276.62% |
| 2011 | -67.5 Million AUD | 85.26% |
| 2010 | -457.95 Million AUD | 68.65% |
| 2009 | -1.46 Billion AUD | -706.95% |
| 2008 | 240.71 Million AUD | -46.2% |
| 2007 | 447.43 Million AUD | 97.61% |
| 2006 | 226.42 Million AUD | -1.36% |
| 2005 | 229.55 Million AUD | -55.22% |
| 2004 | 512.6 Million AUD | 53.82% |
| 2003 | 333.25 Million AUD | 10.73% |
| 2002 | 300.97 Million AUD | 15.76% |
| 2001 | 259.99 Million AUD | 156740.83% |
| 2000 | -165.98 Thousand AUD | -104.11% |
| 1999 | 4.04 Million AUD | -44.76% |
| 1998 | 7.31 Million AUD | -73.09% |
| 1997 | 27.18 Million AUD | -2.79% |
| 1996 | 27.96 Million AUD | -21.83% |
| 1995 | 35.78 Million AUD | 50.98% |
| 1994 | 23.69 Million AUD | 2211.3% |
| 1993 | 1.02 Million AUD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 11.09 Billion USD | 0.0% |
| 2024 Q1 | 17.1 Billion USD | 60.18% |
| 2024 Q4 | 10.52 Billion USD | 0.0% |
| 2024 FY | 10.52 Billion USD | -1.43% |
| 2023 Q2 | 10.61 Billion USD | -35.48% |
| 2023 Q1 | 16.44 Billion USD | 2212.13% |
| 2023 FY | 10.67 Billion USD | 1471.56% |
| 2023 Q4 | 10.67 Billion USD | -32.57% |
| 2023 Q3 | 15.83 Billion USD | 49.26% |
| 2022 Q4 | -778.6 Million USD | 32.01% |
| 2022 Q1 | -1.05 Billion USD | -126.5% |
| 2022 Q2 | -765.6 Million USD | 27.74% |
| 2022 Q3 | -1.14 Billion USD | -49.58% |
| 2022 FY | -778.6 Million USD | -119.47% |
| 2021 Q1 | 5.17 Billion USD | -26.03% |
| 2021 Q3 | 5.15 Billion USD | 39.35% |
| 2021 Q4 | 3.99 Billion AUD | -22.51% |
| 2021 FY | 3.99 Billion AUD | -16.68% |
| 2021 Q2 | 3.7 Billion USD | -28.41% |
| 2020 FY | 4.79 Billion AUD | 19.81% |
| 2020 Q3 | 7.67 Billion USD | 55.37% |
| 2020 Q4 | 6.99 Billion AUD | -8.91% |
| 2020 Q1 | 7.31 Billion USD | 82.76% |
| 2020 Q2 | 4.94 Billion USD | -32.51% |
| 2019 FY | 4 Billion AUD | 12.13% |
| 2019 Q3 | 5.63 Billion USD | -0.32% |
| 2019 Q1 | 5.51 Billion USD | 54.29% |
| 2019 Q2 | 5.65 Billion USD | 2.61% |
| 2019 Q4 | 4 Billion AUD | -28.94% |
| 2018 Q3 | 4.64 Billion USD | 0.6% |
| 2018 FY | 3.57 Billion AUD | 14.08% |
| 2018 Q1 | 4.59 Billion USD | 46.76% |
| 2018 Q2 | 4.61 Billion USD | 0.5% |
| 2018 Q4 | 3.57 Billion AUD | -23.11% |
| 2017 Q2 | 3.66 Billion USD | 6.07% |
| 2017 FY | 3.13 Billion AUD | 21.03% |
| 2017 Q4 | 3.13 Billion AUD | -23.52% |
| 2017 Q3 | 4.09 Billion USD | 11.71% |
| 2017 Q1 | 3.45 Billion USD | 33.56% |
| 2016 Q1 | 2.81 Billion USD | 63.56% |
| 2016 FY | 2.58 Billion AUD | 50.03% |
| 2016 Q3 | 3.36 Billion USD | 23.52% |
| 2016 Q2 | 2.72 Billion USD | -3.47% |
| 2016 Q4 | 2.58 Billion AUD | -23.07% |
| 2015 Q3 | 2.25 Billion USD | 45.55% |
| 2015 FY | 1.72 Billion AUD | 34.53% |
| 2015 Q1 | 1.45 Billion USD | 13.24% |
| 2015 Q2 | 1.55 Billion USD | 6.9% |
| 2015 Q4 | 1.72 Billion AUD | -23.65% |
| 2014 Q1 | 1.17 Billion USD | 28.13% |
| 2014 Q3 | 1.37 Billion USD | 12.32% |
| 2014 Q2 | 1.22 Billion USD | 4.51% |
| 2014 FY | 1.28 Billion AUD | 39.81% |
| 2014 Q4 | 1.28 Billion AUD | -7.05% |
| 2013 Q1 | -729.26 Million USD | -711.67% |
| 2013 Q2 | -728.81 Million USD | 0.06% |
| 2013 Q3 | 877.54 Million USD | 220.41% |
| 2013 Q4 | 916.7 Million AUD | 4.46% |
| 2013 FY | 916.7 Million AUD | 668.88% |
| 2012 Q4 | 119.22 Million AUD | 0.0% |
| 2012 FY | 119.22 Million AUD | 276.62% |
| 2011 Q4 | -67.5 Million AUD | 0.0% |
| 2011 FY | -67.5 Million AUD | 85.26% |
| 2010 FY | -457.95 Million AUD | 68.65% |
| 2010 Q4 | -457.95 Million AUD | 0.0% |
| 2009 Q4 | -1.46 Billion AUD | 0.0% |
| 2009 FY | -1.46 Billion AUD | -706.95% |
| 2008 Q4 | 240.71 Million AUD | 0.0% |
| 2008 FY | 240.71 Million AUD | -46.2% |
| 2007 Q4 | 447.43 Million AUD | 0.0% |
| 2007 FY | 447.43 Million AUD | 97.61% |
| 2006 FY | 226.42 Million AUD | -1.36% |
| 2006 Q4 | 226.42 Million AUD | 0.0% |
| 2005 FY | 229.55 Million AUD | -55.22% |
| 2005 Q4 | 229.55 Million AUD | 0.0% |
| 2004 Q4 | 512.6 Million AUD | 0.0% |
| 2004 FY | 512.6 Million AUD | 53.82% |
| 2003 Q4 | 333.25 Million AUD | 0.0% |
| 2003 FY | 333.25 Million AUD | 10.73% |
| 2002 FY | 300.97 Million AUD | 15.76% |
| 2002 Q4 | 300.97 Million AUD | 0.0% |
| 2001 Q4 | 280.51 Million AUD | 0.0% |
| 2001 FY | 259.99 Million AUD | 156740.83% |
| 2000 Q4 | -222.21 Million AUD | 0.0% |
| 2000 FY | -165.98 Thousand AUD | -104.11% |
| 1999 Q4 | 4.04 Million AUD | 0.0% |
| 1999 FY | 4.04 Million AUD | -44.76% |
| 1998 Q4 | 7.31 Million AUD | 0.0% |
| 1998 FY | 7.31 Million AUD | -73.09% |
| 1997 Q4 | 27.18 Million AUD | 0.0% |
| 1997 FY | 27.18 Million AUD | -2.79% |
| 1996 FY | 27.96 Million AUD | -21.83% |
| 1995 FY | 35.78 Million AUD | 50.98% |
| 1994 FY | 23.69 Million AUD | 2211.3% |
| 1993 FY | 1.02 Million AUD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | 803511550.382% |
| Arch Therapeutics, Inc. | 5.64 Million USD | -186254.647% |
| Evofem Biosciences, Inc. | 42.79 Million USD | -24497.481% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 4216909.551% |
| Rebus Holdings, Inc. | 305 Thousand USD | -3451047.541% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 167059.472% |
| Qrons Inc. | 351.42 Thousand USD | -2995116.645% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -1691193.198% |
| Adynxx, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | -24134.471% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 51577912.623% |
| Skye Bioscience, Inc. | -5.72 Million USD | 184076.304% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | -66676.629% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | -255508.029% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -2619291.861% |
| SQZ Biotechnologies Company | -36.23 Million USD | 29146.857% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | -469342.739% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -1135163.043% |
| Mesoblast Limited | 55.85 Million USD | -18744.126% |
| Marizyme, Inc. | 18.56 Million USD | -56585.786% |
| Genus plc | 190.6 Million USD | -5422.56% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | -470686.714% |
| Pharming Group N.V. | 109.8 Million USD | -9486.172% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -1223510.593% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -867031.07% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -1547841.176% |
| ContraFect Corporation | -6.02 Million USD | 174776.402% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -7817842.795% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -910903.619% |
| IMV Inc. | 7.67 Million USD | -137126.663% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | -191215.866% |
| MultiCell Technologies, Inc. | 90.04 USD | -11690359740.071% |
| ONE Bio Corp. | 9.04 Million USD | -116337.602% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 1434202.93% |
| RVL Pharmaceuticals plc | 12.94 Million USD | -81206.967% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | -769360.756% |
| Q BioMed Inc. | 4.06 Million USD | -259160.573% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | -34350.481% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -1044440.327% |
| Biomind Labs Inc. | 711.4 Thousand USD | -1479513.496% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | -17285.2% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | -526360.044% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | -82092.059% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -2926146.143% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -7529012.186% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -52982232.511% |
| Curative Biotechnology, Inc. | 2.2 Million USD | -477924.106% |
| GB Sciences, Inc. | 1.74 Million USD | -602309.639% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 5727350.963% |
| HST Global, Inc. | 96.79 Thousand USD | -10874653.34% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -5104231.845% |
| Halberd Corporation | 144.72 Thousand USD | -7273205.187% |
| Enzolytics Inc. | 981.65 Thousand USD | -1072169.716% |
| Agentix Corp. | 37.63 Thousand USD | -27971519.144% |
| Resverlogix Corp. | 6.45 Million USD | -163068.501% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 1563934.797% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 618.818% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 22490.028% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -148762.137% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -388511.892% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 119173.584% |
| AVAX Technologies, Inc. | -5.9 Million USD | 178409.858% |
| Zenith Capital Corp. | 10.06 Thousand USD | -104590520.032% |
| Genscript Biotech Corporation | -1.06 Billion USD | 1091.77% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -5251556.422% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | -441050.461% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -6398334.128% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 57462705.088% |
| Kadimastem Ltd | -253.1 Thousand USD | 4158897.639% |
| Helix BioMedix, Inc. | -2.57 Million USD | 409666.885% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | -51813.592% |
| BioStem Technologies, Inc. | 4.47 Million USD | -235275.092% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -5230106.605% |
| LadRx Corporation | -2.03 Million USD | 516975.042% |
| Cell Source, Inc. | 9.23 Million USD | -113916.823% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -1657101.964% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -1657101.964% |
| NovAccess Global Inc. | 2.17 Million USD | -483084.26% |
| Affymax, Inc. | -5.59 Million USD | 188165.035% |
| Itoco Inc. | 228.3 Thousand USD | -4610399.113% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -7740231.939% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | -212246.177% |
| Mobile Lads Corp. | 484.23 Thousand USD | -2173651.425% |
| CytoDyn Inc. | 20.26 Million USD | -51849.462% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 1626893453.941% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 113569520.198% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | -136494.826% |
| SYBLEU INC | 473.71 Thousand USD | -2221915.815% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | -236066.66% |
| International Stem Cell Corporation | 2.59 Million USD | -406309.266% |
| Bioxytran, Inc. | 1.89 Million USD | -554216.836% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -16864976.186% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -482544.78% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | -306423.005% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | -122967.929% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -1362300.289% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 842180.0% |
| Neutra Corp. | 52.18 Thousand USD | -20169674.082% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 423000.763% |
| PureTech Health plc | -167.19 Million USD | 6395.568% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 4298040.451% |
| IXICO plc | -4.44 Million USD | 236927.404% |
| IntelGenx Technologies Corp. | 13.21 Million USD | -79527.808% |
| Gelesis Holdings, Inc. | 54.85 Million USD | -19090.17% |
| CSL Limited | 10.52 Billion USD | 0.0% |
| Cellectis S.A. | -43.81 Million USD | 24121.613% |